| Code | CSB-RA751020MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NGM-120, targeting GFRAL (GDNF family receptor alpha-like), a recently discovered receptor highly expressed in the brainstem area postrema. GFRAL functions as the primary receptor for GDF15 (growth differentiation factor 15), mediating critical physiological responses including appetite suppression, energy expenditure regulation, and metabolic homeostasis. The GFRAL-GDF15 signaling axis has emerged as a key pathway in metabolic disorders, cachexia, and cancer-associated anorexia, as elevated GDF15 levels correlate with weight loss and metabolic dysfunction in various disease states.
NGM-120, the reference antibody developed by NGM Biopharmaceuticals, is a fully humanized monoclonal antibody designed to block GFRAL-GDF15 interactions. This biosimilar provides researchers with a valuable tool for investigating GFRAL-mediated signaling mechanisms, exploring therapeutic interventions for cachexia and metabolic diseases, and studying the physiological roles of GDF15 in appetite regulation and energy balance. It enables detailed mechanistic studies of this emerging therapeutic target in preclinical research settings.
There are currently no reviews for this product.